News | August 16, 2021
Orchid Pharma reports net loss of Rs 30.90 cr in Q1FY22
EPS for the period at Rs. (7.57)
EPS for the period at Rs. (7.57)
The company reports revenue growth of 26% and PAT growth of 21% YoY
_256_384.jpg)
The antiviral technology involves the presence of active positive charges on the fabric, as binding sites for viruses and on contact with the fabric, virus cells that are negatively charged are neutralised, leading to the rapid destruction of their glycoprotein layers and the release of non-infectious ribonucleic acid (RNA)
The group has a total of 320 ANDA approvals
The notification implies that any export of Rapid Antigen Kit will require a licence or permission from DGFT
The MoU was signed on World Organ Donation Day which falls on August 13
This is the first of its kind vaccine for Covid 19 to get the go-ahead
It falls under the Department of Biotechnology - Mission Covid Suraksha Project for augmenting manufacturing capacity for Covaxin
This therapy may provide the first potential oral treatment for COVID-19, recognizing the global emergency of new SARS-CoV-2 variants
Subscribe To Our Newsletter & Stay Updated
